HBV

HBV смотреть последние обновления за сегодня на .

Drawn to Science | HBV virus | The little big enemy

39155
192
9
00:03:18
15.07.2013

Viruses are self-replicating nano-machines that stride the border between living and non-living. The hepatitis B virus in its chronic form can nest in the liver for years, sometimes as a tiny fragment of cyclic DNA. It is estimated that about 360 million people worldwide have chronic HBV infection, 75 percent being in Asia. Roche pRED (Pharma Research & Early Development) has active research programs targeting the hepatitis B virus. For more information visit 🤍 More videos on 🤍

Hepatitis B: Explained

193083
1615
600
00:07:03
05.02.2021

As the most common liver disease in the world, Hepatitis B is a life-threatening liver infection caused by the hepatitis B virus, or HBV. It can cause chronic infection and put people at a high risk of death from cirrhosis (scarring of the liver) and liver cancer. In 2015, 257 million people were living with a chronic form of hepatitis B, and almost 900,000 people died from it. In this video, you’ll learn a bit about the background of hepatitis B, its symptoms, transmission, molecular mechanism, prevention, and treatment! This video was made by McMaster University Demystifying Medicine students Julie Cho, Saad Ahmed, Vivek Parmar, Anisa Rana, Barjot Gill. Copyright McMaster University 2021. References: Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Vincenzo, P. D., Giuberti, T., . . . Ferrari, C. (2007). Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. Journal of Virology, 81(8), 4215-4225. doi:10.1128/jvi.02844-06 Hepatitis B Foundation. (2020). What is Hepatitis B. 🤍 Janeway C. et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. T cell-mediated cytotoxicity. Available from: 🤍 Lumley SF, McNaughton AL, Klenerman P, Lythgoe KA and Matthews PC (2018) Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. Front. Immunol. 9:1561. doi: 10.3389/fimmu.2018.01561 Oh, I., & Park, S. (2015). Immune-mediated Liver Injury in Hepatitis B Virus Infection. Immune Network, 15(4), 191. doi: 10.4110/in.2015.15.4.191 Schuch, A., Hoh, A., & Thimme, R. (2014). The role of natural killer cells and CD8+ T cells in hepatitis B virus infection. Frontiers in immunology, 5, 258. doi: 10.3389/fimmu.2014.00258 Seeger, C., & Mason, W. S. (2015). Molecular Biology of Hepatitis B Virus Infection. Virology, 0, 672–686. 🤍 WHO. (2020). Hepatitis B. 🤍 Ye, B. et al. (2015). T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death & Disease, 6(3), e1694-e1694. doi: 10.1038/cddis.2015.42

Understanding Hepatitis B Serology Results

366376
10953
466
00:10:30
16.02.2019

This video contains a detailed and simplified explanation how to test for hepatitis B and how to interpret the results of hepatitis B serology. Written notes on hepatitis can be found here: 🤍 Special thanks to Harry Watchman for editing the audio. Zero to Finals Medicine book: UK: 🤍 US: 🤍 Zero to Finals Paediatrics book: UK: 🤍 US: 🤍 Zero to Finals Obstetrics and Gynaecology book: UK: 🤍 US: 🤍 Website: 🤍 Notes: 🤍 Multiple Choice Questions: 🤍 Instagram: 🤍 Facebook: 🤍 Twitter: 🤍 DISCLAIMER: This video is for education and entertainment only, and is not medical advice. This video should NOT be used for medical advice or to guide clinical practice. The Zero to Finals content should not be used in any way to guide medical decision making. Zero to Finals takes no responsibility for any actions taken or not taken based on the information provided. Local and national guidelines and senior clinicians are there to help you make decisions, not YouTube videos. If you need medical advice or information, seek it from an appropriately trained and licenced doctor or healthcare provider that can address your individual needs. Zero to Finals cannot guarantee the accuracy of information in this video. Please highlight any errors you notice in the comments below - thank you.

Hepatitis B virus | Structure, replication, transmission

30069
360
64
00:09:19
20.04.2022

Hepatitis B virus | Structure, replication, transmission - This virology lecture explains about the Hepatitis B virus | Structure, replication, transmission. Hepatitis B virus (HBV) is a serious global health problem. Each year, 1.34 million people die from HBV-related liver diseases. Most of those who die are children under the age of 5. This video provides information on hepatitis B, including the causes, symptoms, and treatments. This video is about a virus that can cause liver damage, called hepatitis B. It covers how the virus is spread, what symptoms to look out for, and how to get medical help if you think you might have contracted it. This is a video about the Hepatitis B virus. The video will talk about what the virus is, how it is spread, who is at risk for getting the virus, and the symptoms of the virus. This is a public service announcement video on the Hepatitis B virus. The video will inform you on what the virus is, how it is spread, the symptoms, and how to protect yourself. If you are sexually active, have multiple partners, or are a drug user, it is important that you watch this video. For more information, log on to- 🤍 Get Shomu's Biology DVD set here- 🤍 Download the study materials here- 🤍 Remember Shomu’s Biology is created to spread the knowledge of life science and biology by sharing all this free biology lectures video and animation presented by Suman Bhattacharjee in YouTube. All these tutorials are brought to you for free. Please subscribe to our channel so that we can grow together. You can check for any of the following services from Shomu’s Biology- Buy Shomu’s Biology lecture DVD set- 🤍shomusbiology.com/dvd-store Shomu’s Biology assignment services – 🤍shomusbiology.com/assignment -help Join Online coaching for CSIR NET exam – 🤍shomusbiology.com/net-coaching We are social. Find us on different sites here- Our Website – 🤍shomusbiology.com Facebook page- 🤍 Twitter - 🤍 SlideShare- 🤍slideshare.net/shomusbiology Google plus- 🤍 LinkedIn - 🤍 Youtube- 🤍 Thank you for watching the virology lecture on Hepatitis B virus | Structure, replication, transmission.

HBV cure update

8436
63
6
00:30:50
03.03.2022

Debika Bhattacharya, MD Associate Clinical Professor University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, United States 24th Bangkok International Symposium on HIV Medicine Virtual Conference on January 19-21, 2022 🤍

Hepatitis B Virus: Serology

84964
1374
14
00:19:18
25.04.2018

Hepatitis B is a viral infection affecting the liver. The disease goes through different phases, which can be diagnosed by serology. Diagnostic testing comprises the three most important parameters: HBs antigen, anti-HBs antibody, and anti-HBc antibody. These three parameters can be used to identify active infection, previous infection, and status after vaccination. In addition, anti-HBc IgM antibodies can be used to confirm acute infection. Outline: 00:00 - Natural course of infection 03:05 - Life cycle of HBV 07:01 - Acute infection 10:41 - Chronic infection 14:50 - Markers 17:33 - Serological diagnostics

Hepatitis B (HBV): Animationsvideo

3176
34
7
00:06:54
07.09.2021

«Was ist ein Hepatitis B Virus?» Dieser kurze Animationsfilm klärt auf und informiert. Für HBV gibt es eine Schutzimpfung. Eine rechtzeitige Behandlung reduziert das Risiko für Zirrhose oder Leberkrebs. Für Patienten mit HBV stehen heute zwei Behandlungsmethoden zur Verfügung.

Interview with Dr. Thomas Tu at the 2022 International HBV Meeting

876
27
00:20:06
27.09.2022

We caught up with the incredibly accomplished Associate Professor, Thomas Tu at the 2022 international HBV Meeting. Thomas Tu, PhD, is an Associate Professor at the Westmead Institute for Medical Research (WIMR) at the University of Sydney Australia. He is the founder of HepBCommunity.org, an online forum for where those living with hepatitis B can connect with peers as well as scientists and clinicians in the field of hepatitis B. Dr. Tu also lives with hepatitis B and is a fierce advocate for those living with the disease. In this interview, The Hepatitis B Foundation’s, Edward Tate, leads Dr. Tu in discussions about HepBCommunity.org, liver cancer and hepatitis B, and progress toward a cure for hepatitis B. Learn more about the International HBV meeting here: 🤍 Learn more about the Hepatitis B Foundation here: 🤍

Hepatitis B Community forum, International HBV Meeting 2022

1240
26
01:41:02
28.09.2022

Researchers and people living with hepatitis B meet in Paris at the third Hepatitis B Community Forum. The Forum is an annual public awareness event co-hosted by the Hepatitis B Foundation and ICE-HBV to provide a powerful conclusion to the International HBV Meeting. The perspectives of the almost 300 million people living with hepatitis B is critical as scientists and clinicians continue working toward hepatitis B cure and elimination, which was the focus of a special session that concluded the 2022 International HBV Meeting. The largest global meeting focused solely on the science of hepatitis B, the HBV Meeting was held this week (Sept. 18-22) in Paris. The Community Forum provided an opportunity for the researchers, physicians and others engaged with hepatitis B to understand the needs of the greater hepatitis B community. Just as important, it allowed those living with hepatitis B to learn about the disease and progress in treatment and a cure directly from the scientists who have made this their life’s work. This year’s Community Forum focused on the European Union, where many hurdles exist in terms of health care inequality, leading to unequal access to hepatitis B screening and treatment, health disparities, stigma and lack of prioritization to eliminate hepatitis B. Following Marinela Debu from ELPA, the European Liver Patients’ Association, organizers and partners “call for equitable access to care in the European Union, so that when the cure comes, it benefits everyone.” The Community Forum was co-hosted by the Hepatitis B Foundation and the International Coalition to Eliminate HBV (ICE-HBV). Foundation President Chari A. Cohen, DrPH, MPH, said: “We truly believe in the concept of ‘nothing about us without us.’ Finding a functional cure for hepatitis B will only be beneficial if we address the structural challenges already faced by people living with hepatitis B.” Fabien Zoulim, MD, PhD, chair of ICE-HBV said, “The forum has become an integral part of the annual international meeting. Inclusion of this audience is pivotal to the success of any progress, which is why the just concluded Community Forum is an essential part of the HBV meeting.” Findings from this year’s Community Forum highlight that, while there is much progress being made towards finding therapies that could lead to functional cure for many people living with hepatitis B, there is still much work to be done to accomplish equitable care. Improved screening systems will be required to ensure an equitable access to cure. Learn more about the International HBV Meeting here: 🤍 Learn more about the Hepatitis B Foundation here: 🤍

Viral hepatitis (A, B, C, D, E) - causes, symptoms, diagnosis, treatment & pathology

1464514
18072
662
00:12:18
22.12.2015

What is the hepatitis virus? Well, the hepatitis virus invades liver cells and causes inflammation in the liver tissue. There are five known hepatitis viruses—hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E, all of which have slightly different presentations, symptoms and severity. Find more videos at 🤍 Hundreds of thousands of current & future clinicians learn by Osmosis. We have unparalleled tools and materials to prepare you to succeed in school, on board exams, and as a future clinician. Sign up for a free trial at 🤍 Subscribe to our Youtube channel at 🤍 Get early access to our upcoming video releases, practice questions, giveaways, and more when you follow us on social media: Facebook: 🤍 Twitter: 🤍 Instagram: 🤍 Our Vision: Everyone who cares for someone will learn by Osmosis. Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: 🤍 Medical disclaimer: Knowledge Diffusion Inc (DBA Osmosis) does not provide medical advice. Osmosis and the content available on Osmosis's properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed health care provider. Always seek the advice of a physician or other qualified healthcare provider with any questions you have regarding a medical condition.

HBV Functional Cure Q&As: For Hepatitis B what does functional cure mean?

3134
31
00:05:00
16.09.2021

Listen to Prof. Seng Gee Lim and Prof. Margaret Hellard discuss what functional cure means for Hepatis B during the event "Finding a Cure for Hepatitis B: Asia-Pacific Regional Webinar." This event, which took place on 29 July 2021 for Hepatitis Day, was co-hosted by ICE HBV, together with Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) and Yellow Warriors Society Philippines (YWSP), Inc. This event was aimed at people living with HBV and their community.

HBV Cure Initiatives: Science in Action, An Expert Review of Current Data

9
0
00:14:32
23.08.2022

Pros and Cons of Withdrawal of HBV Therapy Accredited AMA/ANCC/ACPE Activity HBV is a most common causes of liver cirrhosis and HCC. Curing persons with HBV infection remains elusive, despite the availablility of effective antiviral therapy. However, the urgency for an HBV cure remains an active area of research. This program will discuss key research advances in the strategies to HBV cure, pros and cons of withdrawal of therapy, and novel antiviral/immunomodulatory therapies. Dr. Nezam Afdhal and Dr. Daryl Lau will lead each of the 15-minute segment presentations with downloadable, supporting PowerPoint slides. Each segment will be available for .25 AMA/ANCC/ACPE credit/contact hour based on confirmed participation and the completion of an evaluation and post-test. FACULTY Nezam Afdhal, MD, DSc Chief, Division of Gastroenterology, Hepatology and Nutrition Beth Israel Deaconess Medical Center Charlotte and Irving Rabb Professor of Medicine Harvard Medical School Daryl Lau, MD, MPH Associate Professor of Medicine Harvard Medical School Director, Translational Liver Research Beth Israel Deaconess Medical Center Review the activity at 🤍 to claim AMA, ANCC, or ACPE credit/contact hour(s) after completion of the brief Post-Test/Evaluation. This activity is jointly provided by the University of Nebraska Medical Center, Duquesne University School of Pharmacy and Practice Point Communications. Supported by an independent educational grant from Gilead Sciences Medical Affairs.

2022 HBV Cure Symposium Promises and challenges of immunotherapies - Part 1

1419
26
33
00:39:08
04.10.2022

The event was aimed at scientists, clinicians, and pharmaceutical and diagnostic industry representatives.  The symposium, chaired by Mala Maini and Antonio Bertoletti, debated challenges surrounding immunotherapies for HBV and discussed ways forward.

What do we need to achieve a Hepatitis B Cure? | HBV Cure FAQs

2027
50
00:06:24
28.07.2022

In this video, Ulrike Protzer, Director of the Institute of Virology at the Technical University of Munich and Helmholtz Munich and TherVacB Coordinator answers the question: What do we need to achieve an HBV Cure? Anti-virals, immune therapries, or both? This is part of the new video series - HBV Cure FAQs: All you need to know to understand HBV research. The HBV Cure FAQs are a new tool aimed at empowering the community by equipping them with the knowledge needed to understand research for a Hepatitis B (HBV) cure that is taking place for their benefit. It is a collection of short videos answering key questions relating to HBV cure research. It is a product of an international consortium of organizations and expert institutions working in and around hepatitis B. The organizations involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, TherVacB, IP-cureB, and the Canadian HBV Network.

Hbv

13969
450
33
00:09:38
14.05.2018

How do we sign up for HBV and HDV clinical trials? | HBV Cure FAQs

412
12
2
00:04:24
20.12.2022

In this video, Chari Cohen, President of the Hepatitis B Foundation answers the question: How do we sign up for HBV and HDV clinical trials? This is part of the new video series - HBV Cure FAQs: All you need to know to understand HBV research. The HBV Cure FAQs are a new tool aimed at empowering the community by equipping them with the knowledge needed to understand research for a Hepatitis B (HBV) cure that is taking place for their benefit. It is a collection of short videos answering key questions relating to HBV cure research. It is a product of an international consortium of organizations and expert institutions working in and around hepatitis B. The organizations involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, TherVacB, IP-cureB, and the Canadian HBV Network.

Ciclo de vida do HBV e mecanismo de ação do Baraclude

9133
157
7
00:08:29
22.04.2013

Vídeo sobre o ciclo de vida do VHB. Belém, 2008.

فيروس بى / hepatitis B virus

109683
3000
471
00:08:46
11.11.2019

علاج فيروس بى الكبدى مع د. تامر احمد عبدالعزيز اخصائى الباطنة العامة

Management of HBV - Test & Treat Strategy | Hailemichael Desalegn, MD

183
6
00:18:10
18.01.2021

Lecture: Management of HBV - Test & Treat Strategy Speaker: Hailemichael Desalegn, MD St. Paul's Hospital Millennium Medical College, Ethiopia Presented at: Conference on Liver Disease in Africa (COLDA) 2020 Learn more about the Conference on Liver Disease in Africa (COLDA) 2021 that will take place from 9 September 2021 to 11 September 2021 via 🤍 Organized by the SHARE Global Health Foundation in close collaboration with regional societies, COLDA 2021 aims at empowering healthcare professionals (HCPs) to diagnose, prevent, treat and achieve a cure for liver diseases for the benefit of patients in Africa. This being the 4th COLDA, we continue to cultivate a platform that provides a unique opportunity for clinicians, researchers, policymakers, industry representatives, and other healthcare professionals in the African region. Together with support from an international community of experts, they will exchange knowledge on the latest developments and achievements in the management of viral hepatitis and liver disease with a special focus on the African context. We aspire to provide you with a highly scientific and educational abstract-driven conference consisting of keynote speeches, state-of-the-art lectures, oral and poster abstract presentations, roundtable discussions, and debates with ample time for discussion. We are certain that the conference will act as a catalyst for translating science into clinical practice while promoting medical education in the field of hepatology and setting up collaborations within the African region. Everyone will have an exceptional opportunity to share and acquire knowledge, and experience a wide spectrum of topics related to liver disease. Registration for the 2021 webinar is open and fee is waived for healthcare professionals via 🤍 For the Enduring Materials of the 2020 edition visit 🤍 For more medical education programs, as well as the latest scientific information, visit 🤍

EPATITE B, silenziosa e letale con l'HBV - Spiegazione

21484
645
19
00:07:13
26.02.2019

Malattia subdola ed insidiosa, spesso difficile da identificare, ma quando si manifesta, per il fegato sono cavoli amari, perchè anche se trattabile, non va assolutamente sottovalutata. øShop I nostri design: 🤍 øSocial Facebook: 🤍 Instagram: 🤍 Sito Web: 🤍

Ciclo do HBV

8555
153
6
00:03:56
11.02.2015

Descrição

HBV Treatment mode of Action

253
3
2
00:00:47
16.03.2018

Webinar HBV Cure 101 Europe

2904
36
01:17:40
30.11.2021

ICE HBV and Liver Patients International partnered up to put together this webinar HBV Cure 101 with a focus on Europe. The webinar took place on 24 November. The purpose of the event was to bring together scientists researching Hepatitis B and the community that is affected. Program: 0:00:00 - Intro and Housekeeping by Capucine Pénicaud 0:02:08 - Opening Remarks George Kalamitsis (Liver Patient International) 0:03:06 - HBV Cure Research 101 by Dr. Fabien Zoulim 0:16:38 - Clinical Perspective on HBV Cure Research by Dr. George Papatheodoridis 0:25:21 - Community Perspective, Hep Active by Silvana Lesidrenska 0:32:26 - The European HBV Patient Registry, TherVac B by Dr. Markus Cornberg 0:41:08 - IPcureB Project & Clinical Trials by Dr. Pietro Lampertico 0:49:26 - HBV and Migrants in Europe Comsava Project by Camila Picchio 0:59:00 Q&A Session & Discussion Some topics in the discussion were: -Trials underway in Eastern Europe (0:59:55) -International (clinical) studies (challenges even within Europe, etc.) - (01:03:33) -Difficulty of doctors (in Bulgaria) finding patients for clinical trials (01:06:17) -How can we influence EU regulations to make international clinical trials easier (01:09:12) -How can we put pressure on EU Parliament so regulation is changing? (01:13:20)

Hepatitis B (HBV): Interview mit Prof. Dr. Dr. med. Nasser Semmo

1209
26
3
00:16:51
08.11.2021

"Was ist HBV?" In diesem Interview klärt uns Prof. Semmo auf wie man sich gegen den HBV schützen kann. Denn mit über 257'000'000 Ansteckungen weltweit, steht die HBV an erster Stelle der viralen Lebererkrankungen und die Tendenz ist immer noch steigend. Prävention in Form der Impfung kann auch Sie schützen! Weitere Informationen: 🤍

Sansure HBV Nucleic Acid One Step Fast Release Method Demo

865
12
0
00:02:30
07.07.2017

Sansure HBV Nucleic Acid One Step Fast Release Method could offer you a fast and accurate HBV DNA result, which is the right choice for the middle or high workload molecular diagnostic laboratory.

replication HBV.mpg

146365
924
60
00:08:42
15.04.2012

ISG Master Class VI : Dr S K Sarin : Diagnosis and Management of HBV in 2020

11178
131
55
01:33:58
09.05.2020

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.

Hepatitis B Community Forum at the 2021 International HBV Meeting (Toronto)

1615
19
01:33:04
08.10.2021

ICE HBV and the Hepatitis B Foundation partnered up to put together the Hepatitis B Community Forum at the 2021 International HBV Meeting held in Toronto. The purpose of the event was to bring together scientists researching Hepatitis B and the community that is affected. Program: 0:01:34 - Orange Shirt Day Introduction by Dr. Carla Coffin Session I: Update on the Global Response to HBV 0:03:17 - Welcoming Remarks by Dr. Timothy Block 0:06:30 - HBV Science 101 by Dr. Thomas Tu 0:15:30 The Road to HBV Cure - New Findings by Dr. John Tavis 0:26:45 Towards HBV Elimination by Dr. Chari Cohen 0:36:19 Q&A Session moderated by Dr. Jordan Feld Session II: The Challenge of Hepatitis B in Canada - Community Forum 0:49:12 - The HBV Epidemic in Canada by Dr. Carla Coffin 1:01:36 - Community Forum Stories from Lived Experiences (Craig, David, and Miral) 1:01:54 Craig 1:05:33 David 1:10:58 Miral 1:15:15 Q&A Session with Community Forum 1:25:17 Closing Remarks by Dr. Harry Janssen

Hepatitis B (HBV): Interview with Prof. Dr. Dr. med. Nasser Semmo

519
13
5
00:16:55
08.11.2021

"What is HBV?" In this interview, Prof. Semmo tells us how you can protect yourself against HBV. With over 257,000,000 infections worldwide, HBV ranks first among viral liver diseases and the trend is still rising. Prevention in the form of vaccination can also protect you! More information: 🤍

What could a Hepatitis B cure look like? | HBV Cure FAQs

2709
40
00:05:19
22.06.2022

In this video, Incoming ICE-HBV Chair, John Tavis, Professor of Virology and Director of the Drug Discovery Institute at Saint Louis University School of Medicine answers the question: What could a could for Hepatitis B look like? This is part of the new video series - HBV Cure FAQs: All you need to know to understand HBV research. The HBV Cure FAQs are a new tool aimed at empowering the community by equipping them with the knowledge needed to understand research for a Hepatitis B (HBV) cure that is taking place for their benefit. It is a collection of short videos answering key questions relating to HBV cure research. It is a product of an international consortium of organizations and expert institutions working in and around hepatitis B. The organizations involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, TherVacB, IP-cureB, and the Canadian HBV Network.

Voetbal HBV 6 6 2022

179
2
0
00:23:07
15.06.2022

🙃😳🤓Hepatitis Viruses (Hepatitis B Virus Part 1)😖😱😳

21395
789
138
00:29:50
05.07.2020

Microbiology (Systematic Virology)

How can a monoclonal antibody treatment contribute to eradicate chronic HBV infection?

1462
0
0
00:02:14
20.12.2022

Current antivirals cannot cure HBV on their own. ADRI-2F3 is a fully human mAb that completely neutralize HBV, removing excess virus and restoring HBV-specific immune responses. This will allow antiviral drugs to be more efficient in HBV eradication. ADRI-2F3 can also be used to prevent mother-to-child HBV transmission, before vaccination, and to prevent HBV reinfection after liver grafts. ━━━━━━━━━━━━━━━━━━━━ Additional Information ──────────────────────────── 🤍 ━━━━━━━━━━━━━━━━━━━━ Social Media ──────────────────────────── 🤍 ━━━━━━━━━━━━━━━━━━━━ Science Animated ──────────────────────────── 🤍 🤍 🤍 🤍 ━━━━━━━━━━━━━━━━━━━━ #antibody #hbv #antibodies ━━━━━━━━━━━━━━━━━━━━

Z@ppsport: HBV Concordia Zeeland

2318
4
0
00:03:04
19.06.2011

Z🤍ppsport van 2005, bij handboogsportvereniging Concordia Zeeland (NB)

Industry Discussion on Combination Therapy for Hepatitis B Cure at ICE HBV Toronto Symposium

2173
33
00:56:23
14.10.2021

Listen to industry representatives from Janssen, Antios Therapeutics, Aligos Therapeutics, Assembly Bio, and Arbutus discuss their perspective on combination therapies for HBV cure. This discussion took place on 30 September 2021 at the ICE HBV Symposium on HBV Cure: The Mechanism Behind Combination Therapies, done around the 2021 International HBV Meeting in Toronto. For more details on the Symposium click here: 🤍 Moderator Harry Janssen Director, Toronto Centre for Liver Disease, Chair of Global Hepatitis Summit and AASLD Hepatitis Special Interest Group asks each panelist what their favorite combination therapy is, then a wider discussion is held. Click the timestamps below to hear specific speakers or about specific topics. 01:50 Doug Mayers Chief Medical Officer and Co-founder of Antios Therapeutics 04:19 Tse-I Lin Vice President, Early Compound Development at Aligos Therapeutics 08:15 Oliver Lenz Senior Scientific Director Clinical Microbiology and Immunology at Janssen 12:10 Michael Sofia Co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. 15:32 William Delaney Chief Scientific Officer at Assembly Bio 18:50 Summary of industry initial responses by Harry Janssen Q&A Discussion 19:33 To what extent do the companies use withdrawal of nucleos analog treatment as a therapeutic option or not? 28:17 Do you think antivirals by itself will do the job or whether we need true immune modifiers? 33:36 Would there be room for partial cure (of HBV?) 39:36 Should we individualize treatment (of HBV)? 43:25 What strategies do your companies see are viable for keeping costs down enough for them to be able to be used in resource limited settings? 46:47 Comments by Massimo Levrero 48:41 What is the time that you think is reasonable for a pure antiviral combination to be used in patients to hope to have these kind of results? 53:12 Closing remarks by Fabien Zoulim and John Tavis

Aria HIV/Syphilis/HBV/HCV Panel Rapid Test Training Video

24066
130
22
00:03:33
14.10.2019

The Aria HIV/Syphilis/HBV/HCV Panel Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and antibodies to HIV-1, HIV-2, Treponema pallidum (Tp), and hepatitis C virus (HCV) in human serum, plasma, or whole blood. It is intended to be used by professionals to aid in the diagnosis of infection with HIV, Syphilis, hepatitis B virus (HBV), and HCV. Any interpretation or use of this preliminary test result must also rely on other clinical findings as well as on the professional judgment of health care providers. Alternative test method(s) should be considered to confirm the test result obtained by this device.

Hepatitis B (HBV): Presentation by Prof. Dr. Dr. med. Nasser Semmo

963
7
8
00:16:02
08.11.2021

"What is HBV?" In this presentation, Prof. Semmo tells us how HBV can develop, what the treatment options are and what the current state of research is. HBV is the most widespread viral liver disease worldwide, with over 257,000,000 infections. Prevention can also protect you: Get vaccinated! More information: 🤍

Holz-Beton-Verbund Decke, HBV DECKE, so wird die Holz-Beton-Verbund-Decke vor Ort gegossen

1016
2
0
00:00:39
21.04.2022

Umfragen zeigen, dass bei Gebäuden in Leichtbauweise der störendste Lärm die Trittschallübertragung ist. Holz-Beton-Verbund-Decken haben eine besonders hohe Masse. Dadruch verbessert sich die Trittschalldämmung dieser hybriden Decken besonders dort, wie die Trittgeräusche am störendsten sind. Holz-Beton-Verbunddecken sind auch statisch hoch leistungsfähig. Gerade bei großen Spannweiten ist diese Bauweise optimal. Mit unserer Roboter-CNC-Anlage haben wir eine optimale Technologie für die aufwändige Bearbeitung der Deckenelemente. Der Beton kann wie hier vor Ort gegossen werden. Aber auch die Vorfertigung der Betonscheibe bei uns im Werk ist möglich. Dann wird die HBV-Decke als fertiges Element auf die Baustelle gebraucht und mit dem Kran versetzt.

Назад
Что ищут прямо сейчас на
HBV 卑猥 olga buzova iraqia comedian Bahu pimrypie 傳道 Yuframe 国奥 55 CRMP Limonchyk 눈의 Freedive гейб Omar hafdi 逆凸 syslinux